Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07157787 · ClinicalTrials.gov registry record · Phase 2

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

A Phase 2 study of Primary Membranous Nephropathy, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
20
Study locations

NCT07157787 is a Phase 2 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants, below the 133-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07157787, a Phase 2 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

Conditions Studied

Primary Membranous Nephropathy

Interventions

  • DRUG Placebo
  • DRUG ALXN1920

Study Locations (20)

Other

  • Research Site - Buenos Aires
  • Research Site - CABA
  • Research Site - Ciudad de Buenos Aires
  • Research Site - Rosario
  • Research Site - Santa Fe
  • Research Site - Santa Fe
  • Research Site - Gosford
  • Research Site - Parkville
  • Research Site - Southport
  • Research Site - Recife
  • Research Site - Salvador
  • Research Site - São Paulo
  • Research Site - São Paulo
  • Research Site - Baotou
  • Research Site - Beijing

California

  • Research Site - Loma Linda
  • Research Site - San Diego

Minnesota

  • Research Site - Minneapolis
  • Research Site - Rochester

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-09-19
Est. Completion 2027-02-12
Phase Phase 2

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07157787

The ClinicalTrials.gov registry entry for NCT07157787 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (77% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07157787 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Minnesota.

Frequently Asked Questions

What is clinical trial NCT07157787 about?

NCT07157787 is a clinical study titled "Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)". The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

What is the current status of trial NCT07157787?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-19. Estimated completion is 2027-02-12.

What conditions does trial NCT07157787 study?

This clinical trial studies the following conditions: Primary Membranous Nephropathy.

What interventions are being tested in trial NCT07157787?

The interventions under investigation include: Placebo (DRUG), ALXN1920 (DRUG).

Who is sponsoring clinical trial NCT07157787?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07157787 being conducted?

This trial has 20 study locations across California, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Membranous Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Membranous Nephropathy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.